Nuwellis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUWE research report →
Price Chart
About the company
Nuwellis, Inc. , a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients.
- CEO
- Michael McCormick
- IPO
- 2012
- Employees
- 38
- HQ
- Eden Prairie, MN, US
Get TickerSpark's AI analysis on NUWE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $314.40K
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.03
- P/B
- 0.12
- EV/EBITDA
- 0.78
- Div Yield
- 0.00%
- Gross Margin
- 70.76%
- Op Margin
- -133.55%
- Net Margin
- -150.50%
- ROE
- -408.34%
- ROIC
- -113.60%
Latest fiscal year · YoY change
- Revenue
- $8.27M-5.4%
- Gross Profit
- $5.12M-12.0%
- Op Income
- $-11,106,000
- Net Income
- $-17,521,000-56.9%
- EPS
- $-7995.20+92.5%
- OCF Growth
- -12.7%
- FCF Growth
- -12.9%
- 52W High
- $1556.10
- 52W Low
- $2.52
- 50D MA
- $5.72
- 200D MA
- $170.69
- Beta
- 0.29
- RSI (14)
- 34
- Avg Volume
- 829.19K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nuwellis posted flat Q3 revenue but improved margins and operating losses, while doubling down on pediatrics, new product launches, and capital-efficient distribution deals.· November 12, 2026
- Q3 revenue was $2.2 million, unchanged year over year, but gross margin improved to 70% from 65%.
- Operating expenses fell to about $3.6 million from about $4.1 million a year ago, helping cut operating loss 24% to about $2.1 million.
- Year-to-date revenue rose 13% to $6.6 million, and console sales increased to 32 from 17, an 88% increase.
- Pediatrics remained the growth driver, with net sales up 20% in Q3 and 26% year to date.
- Management added two complementary product agreements and filed a 510(k) to expand Aquadex’s pediatric indication to patients as low as 5 kilograms.
Third-quarter 2026 revenue was $2.2 million, flat year over year, and gross profit was approximately $1.5 million with gross margin of 70% versus 65% in the prior-year quarter. Operating expenses were approximately $3.6 million, down from approximately $4.1 million a year ago and approximately $4.7 million in Q2 2026, and operating loss improved 24% year over year to about $2.1 million. Reported net loss was approximately $2 million versus net income of approximately $0.5 million in the prior-year quarter, which included a significant noncash warrant-related gain. For the first nine months of 2026, revenue was $6.6 million, up 13% year over year, and the company sold 32 consoles versus 17 last year. Nuwellis ended the quarter with approximately $8.3 million in cash and cash equivalents, which management said provides runway through Q2 2027. No formal next-quarter or full-year revenue guidance was provided; management instead pointed to continued focus on increasing recurring circuit revenue, reducing cash usage, and progressing 2027 product launches.
Mike McCormick framed the quarter as meaningful operational progress, emphasizing discipline on spending, higher average selling prices, and a stronger gross margin profile. He highlighted pediatrics as the main growth driver and said the ULTRA-Peds publication and the subsequent 510(k) filing are key to expanding Aquadex’s addressable pediatric population. He also stressed that the new Atrility Medical and Zorro-Flow agreements broaden the platform in a capital-efficient way and support growth into 2027.
Carisa Schultz focused on the financial improvement story: Q3 revenue was $2.2 million, gross profit was about $1.5 million, and gross margin rose to 70% from 65%. She said operating expenses declined to about $3.6 million from about $4.1 million a year ago, driving a 24% improvement in operating loss to about $2.1 million. She also detailed liquidity actions, citing $3.4 million in gross proceeds from a registered direct offering, $3.3 million from warrant exercises, and $1.4 million in net proceeds from the ATM, ending with about $8.3 million in cash and runway through Q2 2027.
There was no analyst Q&A because no questions were in queue. As a result, no additional concerns or clarifications were raised beyond management’s prepared remarks.
The call showed improving unit economics, with gross margin at 70% and operating losses down meaningfully even as the company continues to invest. Management also pointed to multiple future catalysts: a pediatric label expansion filing, 2027 launches for SmartView and Pressure IQ, and new distribution deals that could add revenue without heavy capital spending.
Revenue was flat year over year in Q3, and management acknowledged the second half faces tougher comparisons after a strong 2025. The company also remains loss-making and dependent on continued execution to convert clinical and product-development progress into sustained commercial growth, while cash runway extends only through Q2 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.0%
- Shares Outstanding
- 92.20K
- Float Shares
- 47.98K
of shares held by institutions
10 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | McCormick Michael Kendrick | other | 0 |
| Apr 28, 26 | WALLER GREGORY D | other | 6,744 |
| Apr 28, 26 | Emerson Martin J | other | 6,744 |
| Apr 28, 26 | Feldshon Archelle Georgiou | other | 6,744 |
| Apr 28, 26 | McDonald David | other | 6,744 |
| Feb 24, 26 | Emerson Martin J | other | 0 |
| Feb 24, 26 | McDonald David | other | 0 |
| Feb 24, 26 | McDonald David | other | 0 |
| Jan 28, 26 | Schultz Carisa | other | 0 |
| Jan 21, 26 | Field Katharyn | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NUWE coverage
Recent articles, reports, and earnings notes.
No research on NUWE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUWE report →Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
globenewswire.com · Nov 19
Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
globenewswire.com · Nov 12
Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
globenewswire.com · Nov 10
Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
globenewswire.com · Nov 5
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
globenewswire.com · Nov 4
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
globenewswire.com · Oct 27
Nuwellis, Inc. (NASDAQ:NUWE) Shares Shorted: Short Interest Up 339.6% in September
defenseworld.net · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.